MediGene AG · LS:A40ESG
MediGene — Q1 2009 Earnings Presentation
15 slides from MediGene's earnings presentation, May 15, 2009
Slide 1: Earnings call Q1/2009
Earnings call Q1/2009 Frankfurt, May 15, 2009 Dr. Frank Mathias, CEO Dr. Thomas Klaue, CFO Dr. Axel Mescheder, CDO & CSO
Slide 2: Forward-looking statements
This presentation contains forward-looking statements - that is, statements related to future, not past, events. These statements may be identified either orally or in writing by words as "expects", "anticipates", "intents", "plans", "believes", "seeks", "estimates", "will", "may" or words of simila
Slide 3: Overview
Overview Dr Frank Mathias
Slide 4: Dr. Frank Mathias appointed as new CEO
Dr. Frank Mathias appointed as new CEO Around 20 years of experience in the marketing of drugs in the field of pharmaceuticals and biotechnology COO at MediGene since April 2008 2003 – 2008: Managing Director at Amgen GmbH, Munich, Germany; before Commercial Director 1996 – 2002: Managing Di
Slide 5: Two reasons for Optimism!
Two reasons for Optimism! Financially in good shape EndoTAG-1 partnering progressing well X5
Slide 6: Financials
Financials Dr Thomas Klaue
Slide 7: Financial results three months 2009
Financial results three months 2009 In million € Q1-2009 Q1-2008 Change Total revenue 11,614 4,990 133 % Cost of sales -7,618 -3,397 124 % Gross profit 3,996 1,593 151 % Operating expenses -6,064 -9,474 -36 % EBITDA -1,860 -7,553 -75 % Operating result -2,068 -7,881 -74 % Taxes 0 665 - Net loss for
Slide 8: Outlook and financial forecast 2009
Outlook and financial forecast 2009: Product revenues further up, losses further down Average monthly cash burn rate for the remaining 9 months 2009 app. € 1,5 million Further revenue growth driven by Eligard® and Veregen® Cost cuttings launched in 2008 become fully effective Operating losse
Slide 9: Strategic Outlook
Strategic Outlook Dr Frank Mathias
Slide 10: Business Update
Business Update Business review initiated upon appointment as CEO • Near-term drivers • Longer-term objectives Eligard ® • Continued growth driven by 6-month depot formulation Veregen ® • Promising start in the US; updates through the year RhuDexTM • Additional pre-clinical tests underway •
Slide 11: EndoTAG-1 partnering ongoing
EndoTAG-1 partnering ongoing Process so far: • Final data from pancreatic cancer trial in October 2008 • Formal initiation of partnering process in November 2008 • Potential partners conducting diligence under CDA Results so far: • Several non-binding term sheets received • Forming the basis of
Slide 12: Deal Considerations
Deal Considerations Economic climate affects all market participants • Pharma still has financial power • Appetite for risk has been diminished Breast cancer data available in H1 2010 • Potential to capture value ahead of data release • Not a hurdle for near-term deal MediGene is in a strong p
Slide 13: Q&A
Q&A
Slide 14: Outlook
Outlook Review Process ongoing • No fixed agenda, results to be discussed with Supervisory Board Business development activities: • Partnering of EndoTAG™-1 • Approval and partnering of Veregen® in Europe Development: • EndoTAG™-1 phase II trial in breast cancer to complete recruitment Finan
Slide 15: MediGene AG contact details
MediGene AG Lochhamer Straße 11 82152 Planegg / Martinsried, Germany Phone: +49 89 85 65 29 00 Fax: +49 89 85 65 29 20 www.medigene.com MediGene Ltd. 57c Milton Park Abingdon, Oxon, OX14 4RX United Kingdom Phone: +44 1235 438600 Fax: +44 1235 438601 MediGene Inc. 10660 Scripps Ranch Blvd., Suite 200